Brokers Set Expectations for Alkermes plc’s FY2026 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Investment analysts at Leerink Partnrs boosted their FY2026 earnings estimates for shares of Alkermes in a report issued on Tuesday, July 9th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn $2.01 per share for the year, up from their prior estimate of $1.91. The consensus estimate for Alkermes’ current full-year earnings is $2.27 per share.

A number of other analysts have also recently issued reports on ALKS. Robert W. Baird began coverage on Alkermes in a research note on Tuesday, March 19th. They set an “outperform” rating and a $37.00 target price for the company. Cantor Fitzgerald increased their price objective on shares of Alkermes from $43.00 to $48.00 and gave the stock an “overweight” rating in a research report on Thursday, May 23rd. Piper Sandler reaffirmed an “overweight” rating and issued a $39.00 target price on shares of Alkermes in a research note on Monday, April 1st. StockNews.com raised Alkermes from a “hold” rating to a “buy” rating in a research note on Friday. Finally, TD Cowen started coverage on Alkermes in a research report on Monday, June 17th. They set a “buy” rating and a $34.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.50.

Alkermes Trading Up 1.1 %

ALKS opened at $23.57 on Thursday. The firm’s fifty day moving average is $24.20 and its two-hundred day moving average is $26.34. The firm has a market cap of $3.99 billion, a PE ratio of 9.32, a price-to-earnings-growth ratio of 0.46 and a beta of 0.47. Alkermes has a twelve month low of $22.01 and a twelve month high of $32.88. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.77 and a current ratio of 3.20.

Alkermes (NASDAQ:ALKS) last released its earnings results on Wednesday, May 1st. The company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.58 by ($0.15). The company had revenue of $350.37 million during the quarter, compared to analyst estimates of $360.26 million. Alkermes had a net margin of 25.17% and a return on equity of 20.31%. The company’s quarterly revenue was up 21.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.10) EPS.

Institutional Investors Weigh In On Alkermes

Institutional investors have recently modified their holdings of the business. GTS Securities LLC increased its stake in shares of Alkermes by 27.6% in the third quarter. GTS Securities LLC now owns 38,106 shares of the company’s stock valued at $1,067,000 after buying an additional 8,243 shares during the period. Graham Capital Management L.P. acquired a new position in Alkermes in the 3rd quarter valued at approximately $1,081,000. Deutsche Bank AG raised its stake in shares of Alkermes by 6.9% during the third quarter. Deutsche Bank AG now owns 217,395 shares of the company’s stock valued at $6,089,000 after acquiring an additional 13,945 shares during the last quarter. Neo Ivy Capital Management acquired a new position in shares of Alkermes during the third quarter worth $564,000. Finally, American Century Companies Inc. increased its holdings in Alkermes by 35.3% in the third quarter. American Century Companies Inc. now owns 878,272 shares of the company’s stock valued at $24,600,000 after purchasing an additional 229,181 shares during the period. Institutional investors own 95.21% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.